DTA-32294-44612
3 vaccinations
1 coded response
2 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 0-4
- ZIP prefix
- 483 / MI
- Registered
- 2022-11-28
- Relationship
- Child or adolescent in my care
- Guardian
- T7D-17407-91701
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2022-07-14
Dose 1 — Pfizer-BioNTech
-
2022-08-04
Dose 2 — Pfizer-BioNTech
-
2022-09-29
Dose 3 — Pfizer-BioNTech
-
2022-11-28
Registered in v-safe
-
2022-12-31
Survey response — 3 months, dose 3, under 3MedDRA: COVID-19, Cough, Rhinorrhoea — Feeling: Good · Be unable to work or attend schoolFree text: COVID - runny nose and coughMedDRA releases: 2024-11 · check-in free text available
- 2023-03-30
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2022-07-14 | Pfizer-BioNTech | No |
| 2 | 2022-08-04 | Pfizer-BioNTech | No |
| 3 | 2022-09-29 | Pfizer-BioNTech | No |
Free text
Release 12 (Under 3) — 3 months, dose 3, under 3
Symptoms: COVID - runny nose and cough
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Cough | · | · | ✓ |
| SD | COVID-19 | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release